Skip to content

Quantoom Bioservices

Active
Public limited companyfounded 20214 yrs activerue de la Maitrise 11, 1400 Nivelles, BelgiumKBO/BCE: BE 0779.337.887
Summary

The computed 12-month bankruptcy probability of Quantoom Bioservices is 2.5% (moderate). For Quantoom Bioservices, at least two filing cycles of the annual accounts are missing. The 2023 annual accounts show equity of €52,468 and a net result of -€35,527. Its solvency ranks better than 90% of 85 sector peers (fiscal year 2023). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.

Checked score

No current score
Figures too old
The available figures for FY 2023 are too old to assess current financial health.
Filing: At least two filing cycles are missing
Axes, FY 2023 · tick = 2022
Profitability0=
Solvency100▲+100
Growth78
Track record94
Bankruptcy probability, 12 months
2.5% Moderate
0%0.5%1.5%4%10%≥ 25%
Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 4 years 0 10 y
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2023
Solvency, return and age of the figures
Solvency
88.9%
Return on assets
-60.2%
Age of the figures
33 mo
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Two or more financial years not filed
Since the financial year that closed on 31-12-2024, 2 financial years are missing at the National Bank. A company this far behind goes bankrupt within the year nineteen times as often as a punctual filer.
NBB · 2 filings
Position against the passed deadline
31-12-2024 close31-07-2025 deadline27-09-2026 today
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2023 was due by 31-07-2024 and was filed on 03-07-2024, 28 days ahead of the deadline.
NBB · 2 filings
Deviation from the deadline
2025
not confirmed
2024
not filed
2023
28 d early
2022
19 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 2 accounts on average 24 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

Quantoom Bioservices was incorporated on 24 December 2021 as a Public limited company.1 The company has filed 2 sets of annual accounts, the latest for fiscal year 2023.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2023

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2023, full schema

Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€35,527▲ 65.7%
2022 · -€103,505
Working capital
€52,468
2022 · -€42,005
Trend over the years

Click a name to add, emphasise or remove a line.

Every figure with its change against the fiscal year before
favourable unfavourable
Line20222023
Operating result-€103,361--€35,024▲ 66.1%
Net result-€103,505--€35,527▲ 65.7%
Equity-€42,005-€52,468
Total assets€66,217-€59,035▼ 10.8%
Debt€108,222-€6,567▼ 93.9%
Working capital-€42,005-€52,468
Result per fiscal year
Operating resultNet result
-€150,000-€100,000-€50,000€0Operating result 2022: -€103,361-€103,361Net result 2022: -€103,505-€103,505Operating result 2023: -€35,024-€35,024Net result 2023: -€35,527-€35,52720222023-€150,000-€100,000-€50,000€0Operating result 2022: -€103,361-€103,000Net result 2022: -€103,505-€104,000Operating result 2023: -€35,024-€35,000Net result 2023: -€35,527-€35,50020222023
The operating result stays negative: a loss of €35,024 in 2023 against €103,361 in 2022; the loss shrinks.
Balance-sheet composition
Equity and liabilities €59,035
Equity €52,468
Debt €6,567
Debt finances 11.1% of the balance-sheet total.
Key figures and ratios
2023 value · change against 2022
Current ratio
8.99▲
2022 · 0.61
Debt to equity
0.13▲
2022 · -2.58
ROE
-67.7%
ROA
-60.2%▲
2022 · -156.3%
Debt ≤ 1 year
€6,567▼
2022 · €108,222
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
Filed annual accounts As filed with the NBB · 2023 against 2022 · 29 lines
Balance sheet Code20222023
Assets
Total assets20/58€66,217€59,035▼
Current assets29/58€66,217€59,035▼
Amounts receivable within one year40/41€6,763€26,867▲
Trade receivables40-€4,316
Other amounts receivable41€6,763€22,551▲
Cash at bank and in hand54/58€59,454€32,168▼
Equity and liabilities
Total equity and liabilities10/49€66,217€59,035▼
Equity10/15-€42,005€52,468▲
Contributions10/11€61,500€61,500=
Capital10€61,500€61,500=
Issued capital100€61,500€61,500=
Profit (loss) carried forward14-€103,505-€9,032▲
Amounts payable17/49€108,222€6,567▼
Amounts payable within one year42/48€108,222€6,567▼
Trade debts44€52,222€6,567▼
Suppliers440/4€52,222€6,567▼
Other amounts payable47/48€56,000-
Income statement Code20222023
Other operating charges640/8€100€483▲
Non-recurring operating charges66A-€50
Gross operating margin9900-€103,261-€34,491▲
Operating profit (loss)9901-€103,361-€35,024▲
Financial charges65/66B€144€504▲
Recurring financial charges65€144€504▲
Profit (loss) for the period before taxes9903-€103,505-€35,527▲
Profit (loss) for the period9904-€103,505-€35,527▲
Profit (loss) for the period to be appropriated9905-€103,505-€35,527▲
Appropriation of the result
Profit (loss) to be appropriated9906-€103,505-€139,032▼
Profit (loss) brought forward from the previous period14P--€103,505
Transfer from equity791/2-€130,000

The notes to these accounts (1 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20222023Change
Other operating charges640/8€100€483▲ 383%
Non-recurring operating charges66A-€50-
Gross operating margin9900-€103,261-€34,491▲ 66.6%
Operating profit (loss)9901-€103,361-€35,024▲ 66.1%
Financial charges65/66B€144€504▲ 250%
Recurring financial charges65€144€504▲ 250%
Profit (loss) for the period before taxes9903-€103,505-€35,527▲ 65.7%
Profit (loss) for the period9904-€103,505-€35,527▲ 65.7%
Profit (loss) for the period to be appropriated9905-€103,505-€35,527▲ 65.7%
Line20222023Change
Assets
Total assets20/58€66,217€59,035▼ 10.8%
Current assets29/58€66,217€59,035▼ 10.8%
Amounts receivable within one year40/41€6,763€26,867▲ 297%
Trade receivables40-€4,316-
Other amounts receivable41€6,763€22,551▲ 233%
Cash at bank and in hand54/58€59,454€32,168▼ 45.9%
Equity and liabilities
Total equity and liabilities10/49€66,217€59,035▼ 10.8%
Equity10/15-€42,005€52,468▲ 225%
Contributions10/11€61,500€61,500=
Capital10€61,500€61,500=
Issued capital100€61,500€61,500=
Profit (loss) carried forward14-€103,505-€9,032▲ 91.3%
Amounts payable17/49€108,222€6,567▼ 93.9%
Amounts payable within one year42/48€108,222€6,567▼ 93.9%
Trade debts44€52,222€6,567▼ 87.4%
Suppliers440/4€52,222€6,567▼ 87.4%
Other amounts payable47/48€56,000--
Line20222023Change
Profit (loss) for the period9904-€103,505-€35,527▲ 65.7%
Operating cash flow (approximation)-€103,505-€35,527▲ 65.7%
Change in cash--€27,286-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2024
03-07
NBB filing Annual accounts filed
fiscal year 2023 · full schema
2023
31-12
Financial Liquidity times 15current ratio 8.99
Current ratio from 0.61 to 8.99; short-term debt falls from €108,222 to €6,567.
12-07
NBB filing Annual accounts filed
fiscal year 2022 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 4 acts read
About the unread acts

We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
4 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Nivelles · 1 establishment unit since 2022
seat establishment The establishment unit on the map
Ground area
3,517 m²
Building footprint
1,386 m²
Volume, LiDAR
7,058 m³
Parcel 25099D0025/00L003, Wallonia · tallest building 7.0 m, ±2 floors. Linked by address, not a title deed.
5 companies at this address See who is registered here
1 establishment unit
Quantoom Bioservices
rue de la Maitrise 11, 1400 NivellesManufacture of basic pharmaceutical products and pharmaceutical preparations
since 20222.329.238.036
1 parcel
Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
25099D0025/00L003 Wallonia 3,517 m² 1 · 1,386 m² 7.0 m · 2 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Structure & network

Owners and holdings

1 owner

Chain of control

  1. UNIVERCELLS 100%
  2. Quantoom Bioservices

Highest known parent: UNIVERCELLS. The sources do not say who stands above it.

Owners 1

Holdings 0

No holding stated in the accounts, acts or LEI register we read.

According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

No current directors or connected companies found in the register.

Similar companies · same sector, comparable size

Of 148 companies in sector 21100 we hold annual accounts for 108. 58 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPublic limited company
Founded24-12-2021
Fiscal year end31-12
Activities, NACEBEL 2025
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
E-invoicing
Not found in the Peppol register

No Peppol card under this enterprise or VAT number. That proves nothing: publishing a card is voluntary.

What can you do?

Try sending from your invoicing software; if that fails, ask the customer whether they already receive via Peppol.

If the customer is not ready yet, you may send the invoice another way, for example as a PDF; if electronically, with their agreement on a secure alternative. That invoice is valid; the customer risks a penalty. FPS Finance

Register as of 27 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.